Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Blin

Showing results (41-50 of 95) with videos related to

Pageof 10
Sort By:
Pharmacoepidemiology and Drug Safety|February 17, 2012
Administrative complexities for a European observational study despite directives harmonising requirementsSinem Ezgi Gülmez, Séverine Lignot-Maleyran, Corinne S de Vries, et al.
Journal of Epidemiology and Population Health|March 20, 2025
Évaluation des attentes des patients et des bénéfices des Allergènes Préparés Spécialement pour un Individu (APSI) dans le traitement des maladies respiratoires allergiques : une cohorte prospective françaiseLaure Carcaillon Bentata, Pascal Demoly, Davide Caimmi, et al.
Epidemiology (Cambridge, Mass.)|February 28, 2008
Impact of prescriber nonresponse on patient representativenessAnnie Fourrier-Réglat, Cécile Droz-Perroteau, Jacques Bénichou, et al.
International Journal of Cardiology|July 4, 2016
Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysisPatrick Blin, François Philippe, Stéphane Bouée, et al.
Stroke|August 9, 2019
Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial FibrillationPatrick Blin, Laurent Fauchier, Caroline Dureau-Pournin, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 23, 2019
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort studyLaurent Fauchier, Patrick Blin, Frédéric Sacher, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|May 10, 2021
Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database AnalysisHenri-Jean Aubin, Caroline Dureau-Pournin, Bruno Falissard, et al.
Allergy|March 8, 2026
Patient-Perceived Benefits of Named-Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real-World Cohort StudyDavide Caimmi, Abdelilah Abouelfath, Régis Lassalle, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|June 8, 2021
Corrigendum to: Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database AnalysisHenri-Jean Aubin, Caroline Dureau-Pournin, Bruno Falissard, et al.
Pharmacoepidemiology and Drug Safety|November 6, 2018
Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative databasePauline Bosco-Lévy, Stéphanie Duret, François Picard, et al.
Pageof 10

Showing results (41-50 of 95) with videos related to

Sort By:
Pageof 10
Pharmacoepidemiology and Drug Safety|February 17, 2012
Administrative complexities for a European observational study despite directives harmonising requirementsSinem Ezgi Gülmez, Séverine Lignot-Maleyran, Corinne S de Vries, et al.
Journal of Epidemiology and Population Health|March 20, 2025
Évaluation des attentes des patients et des bénéfices des Allergènes Préparés Spécialement pour un Individu (APSI) dans le traitement des maladies respiratoires allergiques : une cohorte prospective françaiseLaure Carcaillon Bentata, Pascal Demoly, Davide Caimmi, et al.
Epidemiology (Cambridge, Mass.)|February 28, 2008
Impact of prescriber nonresponse on patient representativenessAnnie Fourrier-Réglat, Cécile Droz-Perroteau, Jacques Bénichou, et al.
International Journal of Cardiology|July 4, 2016
Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysisPatrick Blin, François Philippe, Stéphane Bouée, et al.
Stroke|August 9, 2019
Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial FibrillationPatrick Blin, Laurent Fauchier, Caroline Dureau-Pournin, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 23, 2019
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort studyLaurent Fauchier, Patrick Blin, Frédéric Sacher, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|May 10, 2021
Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database AnalysisHenri-Jean Aubin, Caroline Dureau-Pournin, Bruno Falissard, et al.
Allergy|March 8, 2026
Patient-Perceived Benefits of Named-Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real-World Cohort StudyDavide Caimmi, Abdelilah Abouelfath, Régis Lassalle, et al.
Alcohol and Alcoholism (Oxford, Oxfordshire)|June 8, 2021
Corrigendum to: Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database AnalysisHenri-Jean Aubin, Caroline Dureau-Pournin, Bruno Falissard, et al.
Pharmacoepidemiology and Drug Safety|November 6, 2018
Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative databasePauline Bosco-Lévy, Stéphanie Duret, François Picard, et al.
Pageof 10